# EDGAR Filing Document

**Accession Number:** 0001262104
**File Stem:** 0000000000-25-008865
**Filing Date:** 2025-8
**Character Count:** 5998
**Document Hash:** 319cdda76b030929ff752e7565d73b94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008865.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0000000000-25-008865

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250820

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lite Strategy, Inc.
- **CENTRAL INDEX KEY:** 0001262104
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 510407811
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-289312

**BUSINESS ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** 858-369-7100

**MAIL ADDRESS:**
- **STREET 1:** 9920 PACIFIC HEIGHTS BLVD
- **STREET 2:** SUITE 150
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MEI Pharma, Inc.
- **DATE OF NAME CHANGE:** 20120629

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARSHALL EDWARDS INC
- **DATE OF NAME CHANGE:** 20030902
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001140361-25-029159

## Text-Extract

```

                                                              August 20, 2025

Justin J. File
Acting Chief Executive Officer
MEI Pharma, Inc.
9920 Pacific Heights Blvd.
Suite 150
San Diego, CA 92121

        Re: MEI Pharma, Inc.
            Registration Statement on Form S-3
            Filed August 6, 2025
            File No. 333-289312
Dear Justin J. File:

       We have conducted a limited review of your registration statement and
have the
following comments.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-3
Cover Page

1.      We note that your disclosure throughout your prospectus is not
consistent as to
        whether the resale offering applies only to the Common Stock or to the
Common
        Stock and the various warrants that appear to be offered for resale.
Please either revise
        throughout, including the following sections as examples of locations
where you only
        address the Common Stock, or revise to remove the resale offering of
the various
        warrants:

              About This Prospectus, page 2;
              Prospectus Summary   The Offering   Selling Stockholders, page 6;
              Prospectus Summary   The Offering   Use of Proceeds, page 6;
 August 20, 2025
Page 2

             Prospectus Summary   The Offering   Plan of Distribution, page 6;
             Prospectus Summary   The Offering   Risk factors, page 6;
             Risk Factors (lead-in paragraph only), page 8;
             Use of Proceeds, page 12;
             Selling Stockholders, page 19 (where you indicate that only Common
Stock are
           being offered and do not include the warrants that are being offered
for resale by
           any of the selling security holders in the table); and
             the fee table (which does not appear to include any of the various
warrants).
2.     We note your disclosure that the selling stockholders may sell the
Securities, which
       you have defined as including all of the various warrants being offered
for resale, at
       varying prices. However, we also note that while your common stock is
listed on
       Nasdaq, the various warrants are not listed or quoted. Therefore, in
order to conduct
       this offering consistent with Rule 415(a)(1)(i) of the Securities Act
and Item 501(b)(3)
       of Regulation S-K, the various warrants may only be resold at an initial
fixed price (or
       a range) unless and until the various warrants are listed or quoted on
an exchange or
       trading market, after which the various warrants may be offered and sold
at prevailing
       market prices or at negotiated prices. Please revise to disclose the
fixed price (or
       range) at which the selling security holders will sell the various
warrants until the
       respective warrants are listed or quoted on an exchange or trading
market, after which
       such warrants may be offered and sold at prevailing market prices or at
negotiated
       prices. Ensure that your "Plan of Distribution" section is revised
accordingly.
3.     If you are offering the various warrants for resale, please make clear
on your cover
       page and in your prospectus summary that there is no established trading
market for
       the various warrants and that you do not intend to apply to list the
various warrants on
       any securities exchange or nationally recognized trading system. We note
your risk
       factor disclosure on page 8 in this regard.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.
 August 20, 2025
Page 3

       Please contact Tim Buchmiller at 202-551-3635 or Chris Edwards at
202-551-6761
with any questions.

                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Life Sciences
cc:   Justin W. Chairman, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._